What is GNLX's market cap?

$88.68M, based on the Nov 4 close of $1.96.

Does Genelux pay a dividend?

No regular cash dividend has been paid in the last year.

How much of GNLX is sold short?

4.6M shares, 12.9% of float, as of Oct 15, 2026.

What sector is GNLX in?

Healthcare, in the Pharmaceuticals industry.

NASDAQ · GNLXHealthcarePharmaceuticals

Genelux Corporation Common Stock (GNLX)

$1.96+2.08%

Close Nov 4, 2026 · split-adjusted

Nov 4, 2026$1.94▼ 76.46% in range

Nov 3, 2025Low $1.91 · High $8.24Nov 4, 2026

What changed · written from our data

As of Nov 4, 2026

Genelux closed at $1.96 on Nov 4, up 2.08%, within 2.6% of its 52-week closing low. Volume of 311.1K shares was 0.67× its 20-day average (below normal).

Split-adjusted performance: -22.8% over one month, -31.7% over six months, -76.2% over one year.

Short interest was 4.6M shares at the Oct 15 settlement, up 6.5% from the prior report (12.9% of float, 15.7 days to cover).

Market cap$88.7M45.2M shares

Revenue · quarter$0.00—

Diluted EPS$-0.21—

P/E · TTM—P/S 11,085.1×

Net margin—

Dividend yieldNone

52-week range1.91 – 8.24−76.2% from high

Volume311.1K0.67× 20-day avg

Volatility · 60d65.8%Annualised

Short % of float12.9%15.7 days to cover

Net cash$18.7MCash $18.7M

Next earnings—Not scheduled

Split-adjusted performance

1W −11.3%1M −22.8%3M −27.4%6M −31.7%YTD −55.0%1Y −76.2%3Y −85.9%5Y —

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum43

Revenue growth—

Net margin—

Value (low P/E)—

Size39

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →

Shares short4.6M+6.5% vs prior

Days to cover15.7Settled Oct 15

% of float12.9%

Short vol. 10d35.5%of daily volume

Closest peers by size in Pharmaceuticals

Company	Price	Today	6M	Rev. growth	Net margin	P/E	Mkt cap
GNLXGenelux	$1.96	+2.08%	−31.7%	—	—	—	$88.7M
PLYXPolaryx Therapeutics	$1.80	+4.05%	−52.6%	—	—	—	$89.7M	Compare
TNXPTonix Pharmaceuticals Holding	$5.11	−1.54%	−65.2%	+577.9%	−299.4%	—	$87.6M	Compare
NTHINeOnc Technologies Holdings	$3.17	+3.26%	−40.3%	—	—	—	$91.3M	Compare
RLYBRallybio	$15.90	+0.25%	+9.2%	−100.0%	—	3.2	$85.6M	Compare
PDSBPDS Biotechnology	$1.30	−7.80%	+22.6%	—	—	—	$94.2M	Compare
VTVTvTv Therapeutics	$24.03	+2.04%	−24.1%	—	—	—	$95.0M	Compare
MISTMilestone Pharmaceuticals	$0.7725	+1.74%	−60.8%	—	−5118.8%	—	$96.2M	Compare
CATXPerspective Therapeutics	$0.8702	−1.11%	−77.2%	−72.1%	−33069.1%	—	$99.3M	Compare

News about Genelux

All news →

No recent articles focused on Genelux.

Quick answers

What does Genelux do?: Genelux Corp is a late-stage biopharmaceutical firm focused on developing oncolytic viral immunotherapies for cancer. Its pipeline includes clinical and preclinical candidates designed to target tumor cells and stimulate an immune response against tumor-specific antigens.
What is GNLX's market cap?: $88.68M, based on the Nov 4 close of $1.96.
Does Genelux pay a dividend?: No regular cash dividend has been paid in the last year.
How much of GNLX is sold short?: 4.6M shares, 12.9% of float, as of Oct 15, 2026.
What sector is GNLX in?: Healthcare, in the Pharmaceuticals industry.

About Genelux

Genelux Corp is a late-stage biopharmaceutical firm focused on developing oncolytic viral immunotherapies for cancer. Its pipeline includes clinical and preclinical candidates designed to target tumor cells and stimulate an immune response against tumor-specific antigens. The company is focused on the development of next-generation oncolytic viral immunotherapies that are designed to generate a personalized multi-prong attack to overwhelm a tumor's sophisticated defense mechanisms.

HQ: Westlake Village, CA26 employeesListed Jan 26, 2023genelux.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology